Live Breaking News & Updates on Dev Mantena

Stay updated with breaking news from Dev mantena. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biological E -- India's next Serum, Bharat Biotech of COVID-19 vaccine


Biological E India s next Serum, Bharat Biotech of COVID-19 vaccine
The acquisition of Akorn India helped Biological E create a potential overall manufacturing capacity of over 1 billion doses per annum.
PB Jayakumar | June 2, 2021 | Updated 23:07 IST
Providence will provide necessary technology transfer for Biological E to manufacture mRNA vaccines in India.
The oldest Indian private vaccine maker, Hyderabad-based Biological E Limited, is emerging as a domestic powerhouse of COVID-19 vaccine manufacturing following its latest deal with Canada-based biotech company Providence Therapeutics.
In addition to the Providence deal, Biological E currently has a couple of in-house COVID-19 vaccines under development and another major manufacturing contract agreement for Johnson & Johnson s single-dose COVID-19 vaccine. It was among the earliest Indian companies to tap potential COVID-19 vaccine opportunities. ....

United States , Baylor College Of Medicine , Elon Musk , Mahima Datla , Hib Hep , Coalition For Epidemic Preparedness Innovations , Akorn Inc , Bioe Holdings Inc , Quad Vaccine Partnership , Serum Institute Of India , Samsung Co , World Health Organization , Central Drugs Standard Control Organization , Biologics Division , Department Of Biotechnology , Expert Committee , Covax Alliance , Hyderabad Based Biologicale Limited , Evans Medicals , United Kingdom Based , Glaxo Smithkline , Baylor College , Dev Mantena , Janssen Pharmaceutica , Janssen Pharmaceutical , Akorn India ,

India's Biological E. to start vaccine late-stage trials in April: Executive


India s Biological E. to start vaccine late-stage trials in April: Executive
SECTIONS
Last Updated: Dec 18, 2020, 05:54 PM IST
Share
Synopsis
The privately held company said in November it had started early-stage and mid-stage human trials of its vaccine candidate, being developed in collaboration with Baylor College of Medicine in Houston and U.S.-based Dynavax Technologies Corp, and expects results by February.
Agencies
Representative Image
BENGALURU: India s Biological E. Ltd plans to start large late-stage trials of its potential COVID-19 vaccine candidate in April next year, according to a top executive at the Hyderabad-based drugmaker.
The privately held company said in November it had started early-stage and mid-stage human trials of its vaccine candidate, being developed in collaboration with Baylor College of Medicine in Houston and U.S.-based Dynavax Technologies Corp, and expects results by February. ....

United States , Andhra Pradesh , Baylor College Of Medicine , U Dynavax Technologies Corp , India Biologicale Ltd , Serum Institute Of India , Baylor College , Dynavax Technologies Corp , Dev Mantena , Serum Institute , Bharat Biotech , ஒன்றுபட்டது மாநிலங்களில் , ஆந்திரா பிரதேஷ் , பேலர் கல்லூரி ஆஃப் மருந்து , சீரம் நிறுவனம் ஆஃப் இந்தியா , பேலர் கல்லூரி , தேவ் மந்டேன , சீரம் நிறுவனம் , பாரத் பயோடெக் ,